Loading...

Brilliant Violet 421™ anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
145-2C11_BV421_1_032911
C57BL/6 mouse splenocytes were stained with CD19 FITC and CD3ε (clone 145-2C11) Brilliant Violet 421™ (above) or Armenian hamster IgG Brilliant Violet 421™ isotype control (below).
  • 145-2C11_BV421_1_032911
    C57BL/6 mouse splenocytes were stained with CD19 FITC and CD3ε (clone 145-2C11) Brilliant Violet 421™ (above) or Armenian hamster IgG Brilliant Violet 421™ isotype control (below).
  • 145-2C11_BV421_2_032911
  • 145-2C11_BV421_CD3_Antibody_IF_012914
    C57BL/6 mouse splenocytes were fixed with 2% paraformaldehyde (PFA), and then stained with 5 µg/ml CD3 (clone 145-2C11) Brilliant Violet 421™ (blue) and 5 µg/ml CD19 (clone 6D5) Alexa Fluor® 647 (red) for 30 minutes at room temperature. The image was captured by 40X objective.
See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability Save
100335 125 µL $176
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100341 50 µg $242
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100336 500 µL $385
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical data sheet

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The immunoglobulin was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
ICC - Verified
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunocytochemistry using the µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed
  2. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  3. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  4. Kiyohara H, et al. 2018. Cell Mol Gastroenterol Hepatol. 7:135. PubMed
  5. Nakagawa S et al. 2017. Cell host & microbe. 22(5):667-677 . PubMed
  6. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  7. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  8. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  9. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  10. Alexander Mildner et al. 2017. Immunity. 46(5):849-862 . PubMed
  11. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  12. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  13. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  14. Qi F, et al. 2019. Front Microbiol. 2.140277778. PubMed
  15. Brown CC, et al. 2020. Cell. 179(4):846-863.e24.. PubMed
  16. Kumar D, et al. 2018. Cancer Prev Res (Phila). 0.895138889. PubMed
  17. Lee C, et al. 2015. Nat Commun. 6: 8477. PubMed
  18. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  19. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  20. Ren Z, et al. 2021. EMBO Molecular Medicine. :e14059. PubMed
  21. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  22. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  23. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  24. Goc J, et al. 2021. Cell. 184:5015. PubMed
  25. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  26. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  27. Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed
  28. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  29. Kuang Z, et al. 2020. Antib Ther. 3:227. PubMed
  30. Hofmann J, et al. 2021. Front Immunol. 11:599495. PubMed
  31. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  32. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  33. Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed
  34. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  35. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  36. Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed
  37. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
  38. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  39. Formaglio P, et al. 2021. Immunity. 54:2724. PubMed
  40. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  41. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  42. Yang N, et al. 2022. NPJ Vaccines. 7:120. PubMed
  43. Gong P, et al. 2022. Cell Death Discov. 8:466. PubMed
  44. Wang S, et al. 2022. Sci Adv. 8:eabn3883. PubMed
  45. Chan L, et al. 2022. Cells. 12: . PubMed
  46. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  47. Játiva S, et al. 2022. Biomed Pharmacother. 153:113415. PubMed
  48. Zhu C, et al. 2022. Chemotherapy. 67:211. PubMed
  49. Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed
RRID
AB_10898314 (BioLegend Cat. No. 100335)
AB_2562556 (BioLegend Cat. No. 100341)
AB_11203705 (BioLegend Cat. No. 100336)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Go To Top Version: 3    Revision Date: 02/18/2014

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account